INFU InfuSystem Holdings, Inc.: Company Value to Revenue

Official company branding of InfuSystem Inc (INFU)

Reliance on long-term contracts with oncology centers and an extensive equipment fleet supports margin growth as InfuSystem Holdings (INFU) scales its business. The EV-to-revenue ratio clearly demonstrates this trend, where 2042.79 captures the current state of the parameter. High cash flow predictability, driven by recurring pump rental payments and the sale of consumables, completes the picture.

InfuSystem (INFU): Enterprise Value-to-Revenue Ratio from 11/23/2025 to 11/20/2026

INFU (InfuSystem): analytical breakdowns and indicator data

- current quotes and average value forecast:
- company stock capitalization data:
Fundamental company valuation:INFU (InfuSystem Inc)
Manufactured products of InfuSystem Holdings, Inc.

Fundamental asset selection requires analyzing business value while accounting for debt load. This indicator compares the enterprise value (EV) of a company to its annual revenue, eliminating the influence of capital structure. For InfuSystem Holdings (INFU), this metric confirms the efficiency of pump fleet management and the transparency of long-term contracts. A stable EV-to-revenue ratio demonstrates the business's actual margin of safety. The trend in the EV-to-revenue level helps distinguish resilience from capital stagnation.

Competitor analysis

ISRG - EV/Sales Multiple|DHR: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple BD (BDX)|Enterprise Value-to-Revenue Ratio STERIS plc|Company Value to Revenue Ratio WST (West Pharmaceutical Services)|Company Value to Revenue BAX (Baxter Corp)|Masimo - Company Value to Revenue Ratio|Stevanato Group S.p.A. - Company Value to Revenue|Total Company Value-to-Revenue Ratio Teleflex Inc (TFX)|MMSI - Enterprise Value-to-Revenue Ratio|Total Company Value-to-Revenue Ratio Envista Holdings Corp NVST|ICUI: EV/Sales Multiple|Company Value to Revenue Ratio XRAY|LMAT (LeMaitre Corp) - EV/Sales Multiple|ATRC (AtriCure Inc) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple STAA|NAGE (ChromaDex Corp) - Business Value to Revenue|ZimVie Inc. - Company Value to Revenue|Total Company Value-to-Revenue Ratio angiodynamics.com (ANGO)|CERS - Enterprise Value-to-Revenue Ratio|TKNO - EV/Sales Multiple|Monogram Technologies Inc (MGRM) - Enterprise Value-to-Revenue Ratio|STSS - Total Company Value-to-Revenue Ratio|UTMD (Utah Medical Products Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple KORU Medical Systems KRMD|Enterprise Value-to-Revenue Ratio Nyxoah SA (NYXH)|Enterprise Value-to-Revenue Coefficient MBOT|EV/Sales Multiple PDEX (Pro-Dex Inc.)|Enterprise Value-to-Revenue Coefficient ZTEK (Zentek Limited)|elutia.com - EV/Sales Multiple|Business Value to Revenue MLSS (milestonescientific.com)|NXGL (NEXGEL Inc.) - Company Value to Revenue|Retractable Technologies - Business Value to Revenue|Enterprise Value-to-Revenue Ratio harvardbioscience.com|Femasys Corp (FEMY) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple MHUA|Predictive Oncology Inc. - Company Value to Revenue Ratio|EV/Sales Multiple CJMB (Callan JMB Inc)|EV/Sales Multiple Atrion Corp ATRI|NeuroMetrix Corporation - EV/Sales Multiple